生殖系转录因子突变(RUNX1、GATA2、CEBPA)患者的继发性白血病
本文综述了生殖系RUNX1、GATA2和CEBPA突变可导致血液肿瘤(常表现为继发性白血病)的认识过程,2016年WHO指南已将这几个基因的生殖系易感性髓系肿瘤纳入分类。文章讨论了这些突变的生物学、临床问题及未解之谜,强调需要全球合作积累纵向数据。
要点
- 生殖系RUNX1、GATA2、CEBPA突变可遗传易感血液肿瘤,常表现为继发性白血病。
- 2016年WHO指南新增了这些基因生殖系易感性髓系肿瘤的分类。
- 生殖系突变携带者在一般人群及临床患者中的发生率仍不明确。
核心结论
- 对生殖系RUNX1、GATA2、CEBPA突变导致的继发性白血病的认识仍在发展中,许多临床和生物学问题尚未解决。
研究设计与样本
- 综述,基于近20年对携带生殖系RUNX1、GATA2、CEBPA突变的家系研究。
主要发现
- 2016年WHO指南将生殖系RUNX1、GATA2、CEBPA等基因易感性髓系肿瘤纳入分类。
- 这些基因的生殖系突变携带者在一般人群或不同临床患者组中的发生率仍不明确。
- 这些基因的体细胞突变在血液肿瘤中常见,且实验室分析常难以区分生殖系突变与体细胞突变。
- 对这些转录因子及其突变等位基因的调控、与其他基因/蛋白/环境的相互作用及其如何改变临床表现的认识仍不完整。
临床怎么用
- 原文未据此给出推荐。
局限性
- 这些基因的生殖系突变携带者在一般人群或各种临床患者组中的发生率仍不明确。
- 实验室分析常难以区分生殖系突变与体细胞突变。
- 对这些转录因子及其突变等位基因的调控、相互作用及对临床表现的影响认识仍不完整。
- 解决剩余临床和生物学问题及有效循证治疗将依赖全球合作积累足够纵向临床和实验室数据并与模型系统整合。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Recognition that germline mutations can predispose individuals to blood cancers, often presenting as secondary leukemias, has largely been driven in the last 20 years by studies of families with inherited mutations in the myeloid transcription factors (TFs) RUNX1, GATA2, and CEBPA. As a result, in 2016, classification of myeloid neoplasms with germline predisposition for each of these and other genes was added to the World Health Organization guidelines. The incidence of germline mutation carriers in the general population or in various clinically presenting patient groups remains poorly defined for reasons including that somatic mutations in these genes are common in blood cancers, and our ability to distinguish germline (inherited or de novo) and somatic mutations is often limited by the laboratory analyses. Knowledge of the regulation of these TFs and their mutant alleles, their interaction with other genes and proteins and the environment, and how these alter the clinical presentation of patients and their leukemias is also incomplete. Outstanding questions that remain for patients with these germline mutations or their treating clinicians include: What is the natural course of the disease? What other symptoms may I develop and when? Can you predict them? Can I prevent them? and What is the best treatment? The resolution of many of the remaining clinical and biological questions and effective evidence-based treatment of patients with these inherited mutations will depend on worldwide partnerships among patients, clinicians, diagnosticians, and researchers to aggregate sufficient longitudinal clinical and laboratory data and integrate these data with model systems.
引用
- Brown AL, Hahn CN, Scott HS, et al. Secondary leukemia in patients with germline transcription factor mutations (RUNX1, GATA2, CEBPA). Blood. 2020. PMID: 32430494. doi:10.1182/blood.2019000937
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。